BridgeBio Oncology Therapeutics (BBOT) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T13:30:41.891Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:30:41.891Z.

Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -198,318,000
Quote market capitalization: 288,385,567
Total debt · period ending 2026-06-30: 2,514,000
Cash · period ending 2026-06-30: 54,063,000

FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

BBOT EBITDA Yield Metrics

EBITDA YIELD

N/A

BBOT Competitors' EBITDA Yield

BBOT

BridgeBio Oncology Therapeutics Inc.

Current

Market Cap

$288.39M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FATE

Fate Therapeutics, Inc.

vs BBOT

Market Cap

$285.57M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INDP

Indaptus Therapeutics, Inc.

vs BBOT

Market Cap

$284.24M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FULC

Fulcrum Therapeutics, Inc.

vs BBOT

Market Cap

$283.83M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACB

Aurora Cannabis Inc.

vs BBOT

Market Cap

$279.05M

EBITDA Yield

N/A

TTM Avg

12.31%

3Y Avg

12.19%

5Y Avg

12.19%

ABEO

Abeona Therapeutics Inc.

vs BBOT

Market Cap

$291.25M

EBITDA Yield

N/A

TTM Avg

6.11%

3Y Avg

6.11%

5Y Avg

6.11%

ACIU

AC Immune S.A.

vs BBOT

Market Cap

$272.75M

EBITDA Yield

N/A

TTM Avg

11.24%

3Y Avg

13.49%

5Y Avg

12.26%

LAB

Standard BioTools Inc.

vs BBOT

Market Cap

$303.11M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IPSC

Century Therapeutics, Inc.

vs BBOT

Market Cap

$269.80M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EYPT

EyePoint Pharmaceuticals, Inc.

vs BBOT

Market Cap

$266.62M

EBITDA Yield

N/A

TTM Avg

10.04%

3Y Avg

10.04%

5Y Avg

9.67%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
BridgeBio Oncology Therapeutics Inc. (BBOT)	$288.39M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$285.57M	N/A	N/A	N/A	N/A
Indaptus Therapeutics, Inc. (INDP)vs ›	$284.24M	N/A	N/A	N/A	N/A
Fulcrum Therapeutics, Inc. (FULC)vs ›	$283.83M	N/A	N/A	N/A	N/A
Aurora Cannabis Inc. (ACB)vs ›	$279.05M	N/A	12.31%	12.19%	12.19%
Abeona Therapeutics Inc. (ABEO)vs ›	$291.25M	N/A	6.11%	6.11%	6.11%
AC Immune S.A. (ACIU)vs ›	$272.75M	N/A	11.24%	13.49%	12.26%
Standard BioTools Inc. (LAB)vs ›	$303.11M	N/A	N/A	N/A	N/A
Century Therapeutics, Inc. (IPSC)vs ›	$269.80M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$266.62M	N/A	10.04%	10.04%	9.67%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

BBOT EBITDA Yield Metrics

BBOT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics